Skip to main content
PLOS One logoLink to PLOS One
. 2020 Jul 10;15(7):e0235709. doi: 10.1371/journal.pone.0235709

Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison

Dolly Baliunas 1,2,*, Laurie Zawertailo 1,3, Sabrina Voci 1, Evgenia Gatov 4, Susan J Bondy 2, Longdi Fu 4, Peter L Selby 1,2,5,6
Editor: Stanton A Glantz7
PMCID: PMC7351500  PMID: 32650339

Abstract

Background

Since 2005, the Smoking Treatment for Ontario Patients (STOP) program has provided smoking cessation treatment of varying form and intensity to smokers through 11 distinct treatment models, either in-person at partnering healthcare organizations or remotely via web or telephone. We aimed to characterize the patient populations reached by different treatment models.

Methods

We linked self-report data to health administrative databases to describe sociodemographics, physical and mental health comorbidity, healthcare utilization and costs. Our sample consisted of 107,302 patients who enrolled between 18Oct2005 and 31Mar2016, across 11 models operational during different time periods.

Results

Patient populations varied on sociodemographics, comorbidity burden, and healthcare usage. Enrollees in the Web-based model were youngest (median age: 39; IQR: 29–49), and enrollees in primary care-based Family Health Teams were oldest (median: 51; IQR: 40–60). Chronic Obstructive Pulmonary Disease and hypertension were the most common physical health comorbidities, twice as prevalent in Family Health Teams (32.3% and 30.8%) than in the direct-to-smoker (Web and Telephone) and Pharmacy models (13.5%-16.7% and 14.7%-17.7%). Depression, the most prevalent mental health diagnosis, was twice as prevalent in the Addiction Agency (52.1%) versus the Telephone model (25.3%). Median healthcare costs in the two years up to enrollment ranged from $1,787 in the Telephone model to $9,393 in the Addiction Agency model.

Discussion

While practitioner-mediated models in specialized and primary care settings reached smokers with more complex healthcare needs, alternative settings appear better suited to reach younger smokers before such comorbidities develop. Although Web and Telephone models were expected to have fewer barriers to access, they reached a lower proportion of patients in rural areas and of lower socioeconomic status. Findings suggest that in addition to population-based strategies, embedding smoking cessation treatment into existing healthcare settings that reach patient populations with varying disparities may enhance equitable access to treatment.

Introduction

Globally, more than 1 billion people smoke tobacco [1]. The World Health Organization Framework Convention on Tobacco Control (WHO FCTC) has endorsed six tobacco control policies to address the global tobacco epidemic: monitor tobacco use and prevention policies; protect people from tobacco use; warn about the dangers of tobacco; enforce bans on tobacco advertising, promotion and sponsorship; raise taxes on tobacco; and offer help to quit tobacco use [1]. Canada is a party to the WHO FCTC, and the province of Ontario has implemented the six endorsed policies since 2005.

Approximately 2 million people in Ontario currently smoke cigarettes [2], and the province spends more than $2 billion dollars annually in direct healthcare costs to treat smoking-related disease [3]. Each year, almost half of Ontarians who smoke try to quit [4], but without help few quit attempts lead to long-term abstinence [5]. Evidence-based treatments can improve quit rates. For example, there is extensive and high-quality evidence that nicotine replacement therapy (NRT) increases the likelihood of quitting smoking by 50% to 60%, irrespective of treatment setting [6]. Further, there is evidence that combining counselling with NRT is more effective than providing either alone [6, 7]. Offering NRT for free or at a reduced cost has been shown to increase the proportion of smokers who make a quit attempt, use smoking cessation treatment, and successfully quit smoking [812]. Based on this evidence, the Smoking Treatment for Ontario Patients (STOP) program was established in 2005, with funding from the government of Ontario, to provide NRT and behavioural support at no cost to Ontarians wanting to quit smoking in a variety of treatment settings. The STOP program has delivered smoking cessation treatment in 11 distinct models, which intentionally vary in recruitment methods, point of contact, mode of delivery, personnel of delivery, intensity of contact and combinations of behavioural support and pharmacotherapies (see Table 1). Models include those engaging people who smoke both directly and through partnering healthcare organizations [1317], via either self-referral or referral from a healthcare practitioner. Since its inception, STOP has utilized a combination of both clinic-based and population-based treatment models. Population-based strategies have been used to distribute a standard supply of NRT with brief counselling, which has included: mail-out of NRT to individuals who enrolled via telephone or website; providing eligible smokers with vouchers for NRT to be redeemed at a local partnering pharmacy; and distributing NRT kits at smoking cessation workshops held at local Public Health Units. Clinic-based models have operated in various primary and specialized care settings across the province, including addictions treatment agencies; treatment in these settings evolved over time from standardized to more personalized in order to provide patients with more intensive pharmacological and behavioural support, as needed.

Table 1. Smoking cessation treatment model characteristics.

Treatment model Timeframe No. (%) No. sites Patient contact Treatment offered Patient eligibility
Behavioural support NRT
Practitioner-mediated
Family Health Team (FHT) 2011–2016 32,618 (30.4) 209 ▪ Visits with a healthcare providera ▪ Individual and/or group ▪ Individualized ▪ Rostered patients
▪ Frequency of visits not prescribed by STOP but recommended every 2–4 weeks ▪ Intensity (number of sessions and minutes per session) not prescribed by STOP ▪ Up to 26 weeks of NRT within 1 year (max of 4 weeks at one visit) ▪ Cigarette smokers wanting to quit, reduce or maintain recent abstinence from smoking
▪ Patches and/or short-acting
Nurse Practitioner-Led Clinic (NPLC) 2014–2016 566 (0.5) 20 ▪ Dosing as per clinical discretion (with medical directive)
Community Health Centre-B (CHC-B) 2012–2016 5,862 (5.5) 59 ▪ May provide standard kit
Addiction Agency (AA) 2012–2016 3,408 (3.2) 49 ▪ Some Addiction Agency sites arrange mail out of 10-week NRT kit following in-person assessment
Tertiary care (hospital-based) 2005–2009 1,672 (1.6) 3 ▪ Visits with a healthcare providera or a smoking cessation specialist ▪ Intensity and frequency of counselling varied, and some patients did not receive counselling ▪ Standard kits ▪ Adults (18+ years)
▪ Up to 10 weeks ▪ Daily smoking 10+ cigarettes
▪ Patch or short-acting ▪ Plan quit attempt within 30 days
▪ On-label use ▪ No contraindications to NRTb
Community Health Centre-A (CHC-A) 2007–2009 401 (0.4) 14 ▪ Visits with a healthcare providera ▪ 3 sessions of brief individual cessation counselling ▪ Standard kits
▪ Up to 10 weeks
▪ Patch or short-acting
▪ On-label use
Workshop 2007–2016 18,539 (17.3) 58 ▪ Group workshop ▪ 1-hour standard psychoeducation presentation ▪ Standard kit
▪ Brief one-on-one consultation with Public Health Unit or STOP staff ▪ 5 or 10 weeks
▪ Patch and/or short-acting
▪ On-label use
Public Health Unit (PHU) 2006–2008 1,509 (1.4) 12 ▪ Visits with Public Health Unit staff ▪ Patient may be referred to optional individual or group counselling if available ▪ Standard kit
▪ Type of counselling varied and was determined by site ▪ Up to 10 weeks
▪ Patch or short-acting
▪ On-label use
Pharmacy (community) 2007–2008 6,412 (6.0) 98 ▪ Web-based enrollment ▪ Brief (5–10 mins) individual counselling ▪ Standard kits
▪ 1–3 visits with pharmacist ▪ Randomized to 1 or 3 sessions ▪ Up to 5 weeks
▪ Patch or short-acting
▪ On-label use
Direct-to-smoker
Web 2008–2009; 2011 6,748 (6.3) NA ▪ Web-based enrollment ▪ Self-help materials ▪ Standard kit sent by mail ▪ Adults (18+ years)
▪ 5 weeks ▪ Daily smoking 10+ cigarettes
▪ Patch or short-acting ▪ Plan quit attempt within 30 days
▪ On-label use ▪ No contraindications to NRTb
Telephone 2006–2010 29,567 (27.6) NA ▪ Telephone call with call centre agent or STOP research staff ▪ Self-help materials ▪ Standard kit sent by mail
▪ 2009: 5 motivational phone messages ▪ 5 to 10 weeks
▪ Patch or short-acting
▪ On-label use

NA = not applicable; NRT = nicotine replacement therapy.

a Healthcare providers include physician, nurse practitioner, registered nurse, registered practical nurse, pharmacist, respiratory educator or therapist, mental health counsellor, addiction counsellor, social worker, health promoter.

b Contraindications to NRT as listed on product monograph at the time of treatment

In addition to increasing the number of quits and quit attempts, the overall goal of the STOP program was also to provide more equitable access to smoking cessation services by reducing geographic and financial barriers to treatment. Smoking is unevenly distributed in the population, with higher prevalence among disadvantaged groups [1820]. Given evidence that smoking cessation programs may widen inequalities in smoking [21] by reaching easier to access and more advantaged populations [22], our objective was to identify and characterize any variation in the population of treatment seeking smokers reached by the different treatment models offered by STOP. Although patients who access the STOP program complete a self-reported baseline survey, data linkage across health administrative datasets provides a unique opportunity to understand who patients are in terms of medical and mental health comorbidity and how they interact with the healthcare system. Combining these data with self-reported measures (e.g., employment status, smoking behaviour), not typically available in healthcare administrative datasets, allows for a picture of the patient population of unprecedented depth and breadth and can influence health policy decisions in Ontario and beyond.

Methods

Study design and population

We conducted a descriptive cross-sectional study of all individuals who sought smoking cessation treatment via the STOP program in Ontario, Canada using self-reported baseline assessment data linked to health administrative data held at ICES (https://www.ices.on.ca/). ICES is an independent, non-profit research institute whose legal status under Ontario’s health information privacy law allows it to hold and use administrative, population health, clinical and other data files for the purposes of analysis, evaluation, and decision support.

We included all individuals aged 18 to 105 years, who enrolled in the STOP program between 18 October 2005 and 31 March 2016. We excluded individuals whose records could not be linked across datasets due to express denial of consent to linkage, missing or invalid linkage information, non-Ontario residence, and records with data inconsistencies (e.g., death date preceding STOP enrollment). The index date was defined as date of enrollment in the STOP program. For individuals who enrolled more than once within the study timeframe, only data related to their first enrollment was used. The 11 treatment delivery models developed and implemented in STOP are described briefly in Table 1; models varied on treatment offered, setting, type and degree of patient contact, patient eligibility criteria, and years of operation. Individuals who enrolled in these models form the comparison groups for this study.

Data sources

The STOP program patient-level enrollment and follow-up survey data were linked to ICES data holdings using a combination of probabilistic and deterministic linkage with a 96% linkage rate. Datasets were linked by means of unique encoded identifiers and analyzed at ICES. To capture sociodemographic information (including age, sex and postal code) for all Ontarians eligible for health coverage, we used the Registered Persons Database [23], a central population registry file which enables linkage across population-based health administrative datasets. We used the 2006 Statistics Canada census [24] to link residential postal code to neighbourhood income quintile; the Immigration, Refugee and Citizenship Canada Permanent Resident database [25] to identify immigration category; and the Rurality Index of Ontario [26] to link postal code to rurality of the community. The following validated prevalent morbidity cohorts were used to determine medical comorbidity: asthma, coronary heart failure, chronic obstructive pulmonary disease (COPD), diabetes mellitus, myocardial infarction (MI), and hypertension (S1 Appendix). We further ascertained presence of a prior cancer diagnosis using the Ontario Cancer Registry [27]. To examine healthcare service utilization, medical hospitalizations were identified through the Canadian Institute for Health Information Discharge Abstract Database [28]. Psychiatric hospitalizations were ascertained using the Ontario Mental Health Reporting System [29], which contains information on all designated adult psychiatric beds in Ontario. Outpatient physician visits were captured through the Ontario Health Insurance Plan database [30], which contains claims for services billed by Ontario physicians. Emergency department (ED) visits were captured through the National Ambulatory Care Reporting System [31]. Lastly, to ascertain health system costs, several additional datasets were used, as described elsewhere (S2 Appendix) [32, 33].

Outcomes

For each individual, descriptive characteristics were measured at index. The following characteristics were derived by self-report from the STOP baseline assessment: employment status, educational attainment, smoking behaviours (number of cigarettes per day, time to first cigarette), and prevalent mental health comorbidities (anxiety, bipolar disorder, depression, schizophrenia). Additional characteristics were derived via linkage to ICES datasets: age, sex, rurality, neighbourhood income quintile, immigrant category, and prevalent medical comorbidities.

Healthcare service utilization and cost outcomes were measured for the period of 2 years up to and including the index date. Healthcare service utilization measures of interest were any visit and median number of visits of the following type: primary care outpatient visits; specialist outpatient visits (overall and mental health and addictions related); ED visits and hospitalizations (overall and mental health and addictions related). For additional details regarding mental health and addictions related outcome definitions, see S3 Appendix. Total healthcare costs were derived by applying a person-centred costing approach using a well-established methodology [32] that uses comprehensive healthcare costs from administrative data for all major sectors of healthcare spending: inpatient hospitalizations, physician visits, complex continuing care, long-term care, home services, assistive devices and pharmaceuticals (for certain individuals, e.g. seniors).

Analysis

For each STOP model, we described the number and proportion of individuals with regard to each of the sociodemographic, clinical, and healthcare service use characteristics at the time of index enrollment. The proportion of missing data on individual characteristics was calculated for each model separately; less than 5% missing data on a characteristic was ignored; 5–10% missing data on a characteristic was noted with a symbol in the relevant table; and where greater than 10% of data was missing, the characteristic was not reported for that model. To examine healthcare service utilization, we ascertained the number and proportion of individuals who had each type of service encounter in the 2 years prior to index, and generated the median number of visits per person. For healthcare costs 2 years prior and including the index, we report median overall cost per person. Statistical analyses were conducted using SAS version 9.4.

Ethics

Each model of the STOP program, as well as this analysis and data linkage, was approved by the Research Ethics Board of the Centre for Addiction and Mental Health (#027/2016, #081/2005, #015/2006, #064/2006, #223/2006, #281/2006, #128/2007, #264/2008, #058/2011, #154/2012). Patients in each model provided written informed consent, with the exception of the Telephone model, where consent was provided over telephone either verbally to a live agent or via an interactive voice response system and recorded in a database.

Results

Study population

Of 132,509 STOP enrollment records between 18 October 2005 and 31 March 2016, we excluded 5,863 records that could not be linked across datasets or had data inconsistencies, and 679 records of non-Ontario residents. We then selected the first enrollment per person, resulting in a cohort of 107,828 unique individuals. After further excluding 526 persons not eligible for provincial health coverage, the final cohort was N = 107,302. Approximately one-third (30.4%) of patients were enrolled in the Family Health Team model, another quarter (27.6%) were enrolled in the Telephone model, 17.3% were enrolled in Workshops, and the rest were distributed across other models.

Sociodemographic and smoking-related characteristics

Patients were not a homogeneous group; there was variation across STOP models with regard to individual characteristics. Enrollees in the Web model had the youngest (39 IQR 29–49) and Family Health Teams the oldest (51 IQR 40–60) median age (Fig 1). Nine of eleven models had a little more than 50% female patients; Addiction Agencies had the lowest proportion of female patients (39.0%). The Family Health Team, Community Health Centre-A, and Public Health Unit models had the highest concentrations of rural enrollees (29.2% to 32.9%) and the Nurse Practitioner-Led Clinics had the lowest (5.5%), followed by the Pharmacy, Web and Telephone models (9.8% to 10.6%). Addiction Agencies had the highest concentration of immigrant and refugee patients (6.4%). The highest proportion of unemployed enrollees was in Addiction Agencies (64.1%) and the lowest in the Pharmacy, Web and Telephone models (<40%, Fig 2). The highest proportion of individuals living in the lowest-income neighbourhood areas were in the Nurse Practitioner-Led Clinic (44.2%) and Community Health Centre-B models (43.0%); the lowest proportion was in Family Health Teams (27.8%). The highest proportion of patients who did not complete high school were in Community Health Centres (≥33%). Lastly, the proportion of patients who self-reported smoking 20+ cigarettes per day and smoking their first cigarette within 5 minutes of waking was highest in the Tertiary Care model (Fig 3).

Fig 1. Select demographic characteristics, by STOP model.

Fig 1

Model (years of operation): FHT = Family Health Team (2011–2016); NPLC = Nurse Practitioner-Led Clinic (2014–2016); CHC = Community Health Centre (A, 2007–2009; B, 2012–2016); AA = Addiction Agency (2012–2016); Tertiary care (2005–2009); Workshop (2007–2016); PHU = Public Health Unit (2006–2008); Pharmacy (2007–2008); Web (2008–2009; 2011); Telephone (2006–2010). aAscertained from the Registered Persons Database. bAscertained using the Immigration, Refugee and Citizenship Canada Permanent Resident database (immigrant and refugee categories were combined to minimize risk of re-identification due to small cell sizes).

Fig 2. Select socioeconomic characteristics, by STOP model.

Fig 2

Model (years of operation): FHT = Family Health Team (2011–2016); NPLC = Nurse Practitioner-Led Clinic (2014–2016); CHC = Community Health Centre (A, 2007–2009; B, 2012–2016); AA = Addiction Agency (2012–2016); Tertiary care (2005–2009); Workshop (2007–2016); PHU = Public Health Unit (2006–2008); Pharmacy (2007–2008); Web (2008–2009; 2011); Telephone (2006–2010). aAscertained using patient self-report in STOP baseline survey. bAscertained using postal code information linked to 2006 census data.

Fig 3. Select smoking-related characteristics, by STOP model.

Fig 3

Model (years of operation): FHT = Family Health Team (2011–2016); NPLC = Nurse Practitioner-Led Clinic (2014–2016); CHC = Community Health Centre (A, 2007–2009; B, 2012–2016); AA = Addiction Agency (2012–2016); Tertiary care (2005–2009); Workshop (2007–2016); PHU = Public Health Unit (2006–2008); Pharmacy (2007–2008); Web (2008–2009; 2011); Telephone (2006–2010). aAscertained using patient self-report in STOP baseline survey.

Comorbid conditions, healthcare service utilization and costs

COPD and hypertension were the most common medical comorbidities across STOP models and most prevalent (about one-third of patients) in Family Health Teams (Table 2). Self-reported mental health comorbidities were prevalent across all models, but most highly prevalent in the Nurse Practitioner-Led Clinic and Addiction Agency models with over 50% of patients reporting lifetime diagnoses by a healthcare provider of anxiety or depression. Direct-to-smoker (Web and Telephone) and Pharmacy models had the lowest comorbidity burden.

Table 2. Patient comorbidities at time of enrollment, by STOP model.

Model FHT NPLC CHC-B AA Tertiary CHC-A Workshop PHU Pharmacy Web Telephone
N = 32,618 N = 566 N = 5,862 N = 3,408 N = 1,672 N = 401 N = 18,539 N = 1,509 N = 6,412 N = 6,748 N = 29,567
Medical comorbidities derived from health administrative data linkage. No. (%)
Asthma 3,059 (9.4) 57 (10.1) 655 (11.2) 433 (12.7) 155 (9.3) 32 (8.0) 1,686 (9.1) 129 (8.5) 428 (6.7) 616 (9.1) 2,283 (7.7)
Cancer 1,537 (4.7) 17 (3.0) 222 (3.8) 85 (2.5) 82 (4.9) 17 (4.2) 724 (3.9) 49 (3.2) 182 (2.8) 155 (2.3) 927 (3.1)
CHF 966 (3.0) 14 (2.5) 163 (2.8) 57 (1.7) 64 (3.8) 350 (1.9) 22 (1.5) 59 (0.9) 81 (1.2) 281 (1.0)
COPD 10,544 (32.3) 142 (25.1) 1,616 (27.6) 813 (23.9) 419 (25.1) 62 (15.5) 4,787 (25.8) 310 (20.5) 877 (13.7) 914 (13.5) 4,938 (16.7)
Diabetes 5,592 (17.1) 80 (14.1) 933 (15.9) 443 (13.0) 246 (14.7) 42 (10.5) 2,412 (13.0) 171 (11.3) 514 (8.0) 547 (8.1) 2,294 (7.8)
Hypertension 10,038 (30.8) 133 (23.5) 1,386 (23.6) 701 (20.6) 440 (26.3) 58 (14.5) 4,699 (25.3) 277 (18.4) 1,083 (16.9) 992 (14.7) 5,245 (17.7)
MI 1,280 (3.9) 17 (3.0) 201 (3.4) 60 (1.8) 129 (7.7) 503 (2.7) 35 (2.3) 78 (1.2) 93 (1.4) 339 (1.1)
Mental health comorbidities derived from STOP survey self-report. No. (%)
Anxiety 10,110 (31.0) 314 (55.5) 2,516 (42.9) 1,682 (49.4)* 507 (30.3) 141 (35.2) 5,420 (29.2) 440 (29.2) ** ** 5,806 (19.6)
Bipolar 1,406 (4.3) 58 (10.2) 557 (9.5) 453 (13.3)* 112 (6.7) 29 (7.2) 996 (5.4) 93 (6.2) ** ** 1,050 (3.6)
Depression 11,676 (35.8) 298 (52.7) 2,827 (48.2) 1,775 (52.1) 616 (36.8) 161 (40.1) 6,303 (34.0) 567 (37.6) ** ** 7,481 (25.3)
Schizophrenia 608 (1.9) 48 (8.5) 337 (5.7) 297 (8.7)* 66 (3.9) 18 (4.5) 513 (2.8) 51 (3.4) ** ** 459 (1.6)

Percent (%) observed are within valid data (missing data ignored) unless otherwise indicated; AA = Addiction Agency, CHC = Community Health Centre, FHT = Family Health Team, NPLC = Nurse Practitioner-Led Clinic, PHU = Public Health Unit, CHF = coronary heart failure, COPD = chronic obstructive pulmonary disease, MI = myocardial infarction;

* proportion of missing 5–10%;

** proportion of missing >10%;

suppressed due to small cell counts (<6).

The proportion of STOP patients who saw a family physician or general practitioner for primary care in the 2 years prior to enrollment was high across all but the Community Health Centre and Nurse Practitioner-Led Clinic models, where such care is more often provided by other practitioner types (Table 3). Addiction Agency and Tertiary Care patients visited primary care providers the most, with a median of 11 visits during this period. Medical hospitalizations were most common among Tertiary Care patients. Addiction Agency patients had the greatest prevalence of outpatient physician visits to a psychiatrist or a primary care provider for mental health and addictions related reasons. However, patients treated for smoking cessation at an Addiction Agency also had the greatest prevalence of specialist physician visits and ED use, and the second greatest prevalence of hospitalizations; with only one third of ED visits and one quarter of hospitalizations being due to mental health and addictions concerns, the vast majority were for physical comorbidities. Lastly, Addiction Agency patients incurred the most health system costs (median $9,393) during the 2 years prior to STOP enrollment, with a median cost five times higher than Telephone patients who incurred the least cost (median $1,787).

Table 3. Healthcare service utilization in the two years prior to enrollment, by STOP model.

Model FHT NPLC CHC-B AA Tertiary CHC-A Workshop PHU Pharmacy Web Telephone
N = 32,618 N = 566 N = 5,862 N = 3,408 N = 1,672 N = 401 N = 18,539 N = 1,509 N = 6,412 N = 6,748 N = 29,567
Outpatient physician visits. No. (%), unless otherwise specified; No. visits reported as Median (IQR)
Primary care 31,077 (95.3) 379 (67.0) 3,645 (62.2) 3,201 (93.9) 1,580 (94.5) 256 (63.8) 16,684 (90.0) 1,376 (91.2) 5,835 (91.0) 5,982 (88.6) 27,055 (91.5)
 No. visits 6 (3–11) 2 (0–7) 2 (0–9) 11 (5–22) 11 (5–20) 1 (0–6) 7 (3–14) 7 (3–15) 7 (3–14) 6 (2–12) 8 (3–15)
Specialist 22,482 (68.9) 428 (75.6) 4,286 (73.1) 2,754 (80.8) 1,312 (78.5) 288 (71.8) 12,487 (67.4) 971 (64.3) 3,851 (60.1) 3,992 (59.2) 17,920 (60.6)
 No. visits 2 (0–6) 3 (1–9) 3 (0–8) 5 (1–13) 4 (1–11) 2 (0–7) 2 (0–7) 2 (0–5) 1 (0–5) 1 (0–5) 1 (0–5)
MHAa 12,920 (39.6) 248 (43.8) 2,331 (39.8) 2,729 (80.1) 1,000 (59.8) 143 (35.7) 8,329 (44.9) 741 (49.1) 2,696 (42.0) 2,843 (42.1) 13,086 (44.3)
 No. visits 0 (0–2) 0 (0–5) 0 (0–3) 6 (1–19) 1 (0–7) 0 (0–1) 0 (0–3) 0 (0–3) 0 (0–2) 0 (0–2) 0 (0–2)
Emergency department (ED) visits. No. (%), unless otherwise specified; No. visits reported as Median (IQR)
Any 20,568 (63.1) 379 (67.0) 3,803 (64.9) 2,545 (74.7) 1,028 (61.5) 216 (53.9) 11,134 (60.1) 1,053 (69.8) 3,542 (55.2) 3,953 (58.6) 15,433 (52.2)
 No. visits 1 (0–3) 1 (0–3) 1 (0–3) 2 (0–5) 1 (0–2) 1 (0–2) 1 (0–3) 1 (0–3) 1 (0–2) 1 (0–2) 1 (0–2)
MHAb,c 2,193 (6.7) 100 (17.7) 767 (13.1) 1,223 (35.9) 179 (10.7) 42 (10.5) 1,570 (8.5) 160 (10.6) 425 (6.6) 507 (7.5) 1,966 (6.6)
Hospitalizations. No. (%), unless otherwise specified; No. visits reported as Median (IQR)
Anyc 5,875 (18.0) 107 (18.9) 1,085 (18.5) 755 (22.2) 462 (27.6) 58 (14.5) 2,729 (14.7) 278 (18.4) 814 (12.7) 936 (13.9) 3,906 (13.2)
MHAb,c 345 (1.1) 105 (1.8) 189 (5.5) 50 (3.0) 7 (1.7) 232 (1.3) 58 (3.8) 88 (1.4) 58 (0.9) 534 (1.8)
Total healthcare cost (Canadian dollars)
Median 3,371 4,965 5,045 9,393 5,586 3,155 3,009 2,618 1,834 1,904 1,787
(IQR) cost (1,260–9,503) (1,486–14,267) (1,482–14,687) (2,779–23,165) (1,663–15,509) (960–8,826) (993–8,952) (888–8,219) (649–5,656) (633–6,213) (610–5,785)

Percent (%) observed are within valid data (missing data ignored) unless otherwise indicated; AA = Addiction Agency, CHC = Community Health Centre, FHT = Family Health Team, NPLC = Nurse Practitioner-Led Clinic, PHU = Public Health Unit, MHA = mental health and addictions;

suppressed due to small cell counts (<6).

a MHA-related outpatient visits include primary care providers (family physicians and general practitioners) and psychiatrists (S3 Appendix).

b For definitions of MHA-related visits to emergency departments and hospitalizations, see S3 Appendix.

c Median (IQR) no. visits = 0 (0–0) for all models and therefore not shown.

Discussion

We compared the characteristics of patients who sought smoking cessation treatment via 11 different models implemented through the STOP program in Ontario between 2005 and 2016, via novel linkage of self-report with health administrative data. Treatment seeking smokers were similar across models on smoking characteristics. However, patients were not homogeneous on sociodemographic and health characteristics across models, highlighting the need to have a variety of treatment delivery options to adequately reach sub-populations who smoke in Ontario.

Though treatment protocols were not modified for each model in an effort to target different sub-populations, a number of factors may have contributed to the observed variation between STOP models. Enrollees in the Web, Telephone and Pharmacy models tended to be of generally higher socioeconomic status, lower comorbidity and younger age. Similarity between patients reached by these models may have been due to the use of similar mass media advertising strategies to promote awareness of the models; the use of different or additional advertising strategies to target specific subgroups (e.g., low-income smokers) may modify the demographic profile of patients seeking care via these models. These models also used similar web-based and telephone screening procedures. Internet and telephone access may have been limited in lower-income smokers [3436], resulting in these models serving more socially advantaged smokers. Our findings are also consistent with prior evidence that individuals with higher levels of education are more likely to use telephone- and Internet-based smoking cessation services [21]. In contrast, practitioner-mediated models in primary or tertiary care settings reached smokers who were more socially disadvantaged and/or had more complex healthcare needs and usage; these models, in which smoking cessation treatment is individualized to the needs of the patient, are well-suited to this more complex patient population [37, 38]. However, even within these settings, there was variation. The Addiction Agency, Community Health Centre-B and Nurse Practitioner-Led Clinic models reached patients with lower socioeconomic status and higher levels of comorbidity and healthcare utilization. Community Health Centres had the highest proportion of patients with low income, and highest levels of comorbidity, consistent with their mandate to serve patients facing barriers to accessing healthcare [39]. The Family Health Team model reached older patients with higher medical comorbidity, but not the most socially disadvantaged. These findings are in contrast with a previous comparison of patient demographics and case-mix of primary care models in Ontario [40], where it was reported that Family Health Teams have somewhat wealthier and healthier populations. Cessation patients in these models were relatively wealthy, but also experienced the poorer health status typical of smokers.

For most models the proportion of rural dwelling patients was close to or greater than the proportion of Ontarians residing in rural communities during the study timeframe (14%-15%) [41, 42]. The Family Health Team model reached the largest number of rural residents, consistent with the overrepresentation of Family Health Teams in rural areas [39] and the large number of patients reached by this model. The earlier Community Health Centre-A and Public Health Unit models reached a higher proportion of rural patients, although this appeared to reflect the location of the small number of sites that partnered in these earlier models. Current models, operating through a larger number of Public Health Units (via the Workshop model) and Community Health Centre sites, have a lower proportion of rural residents. Although direct-to-smoker models were expected to have fewer barriers to access, particularly those related to geography, they reached a lower proportion of rural patients. The reasons are unclear but may be related to the presence of additional barriers in rural communities, such as lower levels of Internet access [35], income and education [43].

Our novel linkage study adds new information to what was previously known about Ontario smokers and their use of the healthcare system. Previous linkage studies have documented increased healthcare service utilization and costs among self-reported smokers in Ontario [40, 44], and demonstrated the effectiveness [45] and cost-effectiveness [46] of a hospital-based smoking cessation treatment program on subsequent healthcare service utilization and mortality. Our study has revealed variation in sociodemographic and health characteristics between smokers served by different treatment models, a comparison not previously reported. While these findings suggest a one-size-fits-all approach to treatment programs may not reflect patient heterogeneity, further work is needed to establish the optimal strategies for tailoring smoking cessation treatment programs for patient populations with different comorbid conditions [47].

Comparing the sociodemographic and health profile of smokers who sought treatment via each of the STOP models can help identify which models are able to reach more vulnerable groups. A disproportionate share of tobacco-related health burden is borne by already disadvantaged groups [48], such as those with lower socioeconomic status or comorbid mental illness, due to increased prevalence of tobacco use, lower cessation rates, barriers to accessing treatment and/or greater vulnerability to associated health risks [49]. Current findings indicate that not all models equally reached socially disadvantaged, and rural dwelling, individuals that traditionally experience greater barriers to accessing treatment. These findings have important implications for efforts to reduce and eliminate tobacco-related health disparities. Evidence from the UK's National Health Service smoking cessation services found that despite lower quit rates in disadvantaged areas, higher reach in these areas lead to a small net positive impact of the services on reducing health inequalities [50]. However, to further reduce inequity, additional research is needed to identify treatment strategies that are effective for individuals with various forms of disadvantage. We are developing and testing methods to address different co-morbidities during smoking cessation treatment in order to improve cessation outcomes (Clinicaltrials.gov registration numbers NCT03108144 and NCT03130998) [51, 52].

We note the importance of considering the context when interpreting findings from the current study, and before generalizing to other settings. Ontario has universal healthcare, and the STOP program, as part of that healthcare infrastructure, has been available to all patients regardless of personal financial means. In a setting where access to health care per se, and specific models of care, may vary based on financial means, comparisons between patient populations reached by different treatment models may reveal lesser or greater disparities or reflect contextual factors not measured in this study (e.g., ethnicity). Implementers in other settings are encouraged to consider and examine factors influencing disparity in their own local context.

Limitations

A potential weakness of this study is selection bias owing to exclusion of patients who declined consent to link their data. Although only 15% of eligible enrollments declined consent for linkage overall, there was variation by model. Decline rate was 0% in the Web, Telephone, Pharmacy and Workshop models and minimal in the Tertiary Care, Public Health Unit and Community Health Centre-A models (<13%). However, the more recently implemented practitioner-mediated models had a higher decline rate (21–29% for the Community Health Centre-B, Nurse Practitioner-Led Clinic and Family Health Team models and 46% in the Addiction Agency model). Overall, records sent for linkage were older, more likely to be unemployed and of lower income, but did not differ on sex. Second, the results of these descriptive analyses do not imply concurrent choice by Ontarian smokers. The models have not been available all at once and patients served by earlier or later models might differ in ways related to time (e.g., changes in healthcare, Internet access, etc.). Further, in practitioner-mediated models, treatment is available only to patients served by individual practices that opted to implement the STOP program. Thus, patients did not have equal opportunity to access different models and comparisons presented are not intended to suggest that patient characteristics are associated with preference for one model over another. Moreover, findings may not generalize to an alternative combination of models.

Conclusions

The current study found that persons seeking to quit smoking through a publicly funded smoking cessation treatment program in Ontario, though similar on smoking characteristics, varied on sociodemographic characteristics and health status according to the setting in which they were enrolled and received treatment. While practitioner-mediated models in specialized and primary care settings reach smokers with more complex healthcare needs that may require more medical supervision, alternative strategies and settings appear better suited to reach younger smokers before such comorbidities develop. These findings suggest that, in the interest of providing equitable access to smoking cessation treatment, the publicly funded healthcare system should ensure that some variation of these model types be available to all residents of Ontario who smoke.

Supporting information

S1 Appendix. Prevalent comorbidity algorithms and associated validation papers.

(PDF)

S2 Appendix. Population-based health administrative datasets used for cost ascertainment.

(PDF)

S3 Appendix. Mental health and addictions-related outcomes.

(PDF)

Acknowledgments

We thank the collaborating organizations, healthcare practitioners and Ontarians served by STOP. We thank Kinwah Fung for methodological support. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI), the Immigration, Refugees and Citizenship Canada (IRCC), and Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of CIHI, IRCC, CCO or the Ontario Ministry of Health and Long-Term Care.

Data Availability

The dataset from this study, composed of STOP program data and ICES datasets, is held securely in coded form at ICES. While data sharing agreements and privacy legislation for the province of Ontario prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at https://www.ices.on.ca/DAS. Requests to access ICES data may be submitted to ICES Data & Analytic Services at das@ices.on.ca, with information available at https://www.ices.on.ca/DAS/Submitting-your-request.

Funding Statement

Funding for this work was provided by a grant from the Ontario Ministry of Health and Long Term Care (http://www.health.gov.on.ca/en/) Health Service Research Fund (#430) to DB and PLS (Co-Is). Funding for STOP was provided by the Ontario Ministry of Health and Long Term Care (#HLTC5047FL) as part of the Smoke Free Ontario Strategy to PLS and LZ (Co-PIs). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. PLS would like to acknowledge salary support for his clinician-scientist position from the Centre for Addiction and Mental Health (www.camh.ca) and the Department of Family and Community Medicine at the University of Toronto (https://www.dfcm.utoronto.ca/).

References

  • 1.World Health Organization. Tobacco [Internet]. Geneva: World Health Organization; 2020 [cited 2020 January 24]. https://www.who.int/news-room/fact-sheets/detail/tobacco.
  • 2.Statistics Canada. Health characteristics, annual estimates [Internet]. Ottawa: Canada; 2020 [cited 2020 March 13]. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009601.
  • 3.Dobrescu A, Bhandari A, Sutherland G, Dinh T. The costs of tobacco use in Canada, 2012. Ottawa: The Conference Board of Canada, 2017.
  • 4.Ontario Tobacco Research Unit. Smoke-free Ontario strategy monitoring report. Toronto: Ontario Tobacco Research Unit; 2016.
  • 5.Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29–38. 10.1111/j.1360-0443.2004.00540.x [DOI] [PubMed] [Google Scholar]
  • 6.Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.van den Brand FA, Nagelhout GE, Reda AA, Winkens B, Evers SM, Kotz D, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2017(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.White CM, Rynard VL, Reid JL, Ahmed R, Burkhalter R, Hammond D. Stop-smoking medication use, subsidization policies, and cessation in Canada. Am J Prev Med. 2015;49(2):188–98. 10.1016/j.amepre.2015.03.001 [DOI] [PubMed] [Google Scholar]
  • 10.Kaper J, Wagena E, Willemsen M, Van Schayck C. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction. 2005;100(7):1012–20. 10.1111/j.1360-0443.2005.01097.x [DOI] [PubMed] [Google Scholar]
  • 11.Schauffler HH, McMenamin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. Tob Control. 2001;10(2):175–80. 10.1136/tc.10.2.175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med. 1998;339(10):673–9. 10.1056/NEJM199809033391006 [DOI] [PubMed] [Google Scholar]
  • 13.Selby P, Voci S, Zawertailo L, Baliunas D, Dragonetti R, Hussain S. Public health impact of a novel smoking cessation outreach program in Ontario, Canada. BMC Public Health. 2018;18(1):1117 10.1186/s12889-018-6012-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zawertailo L, Dragonetti R, Bondy SJ, Victor JC, Selby P. Reach and effectiveness of mailed nicotine replacement therapy for smokers: 6-month outcomes in a naturalistic exploratory study. Tob Control. 2013;22(3):e4 10.1136/tobaccocontrol-2011-050303 [DOI] [PubMed] [Google Scholar]
  • 15.Costello MJ, Sproule B, Victor JC, Leatherdale ST, Zawertailo L, Selby P. Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 smokers. Cancer Causes Control. 2011;22(2):167–80. 10.1007/s10552-010-9672-9 [DOI] [PubMed] [Google Scholar]
  • 16.Zawertailo LA, Baliunas D, Ivanova A, Selby PL. Individualized treatment for tobacco dependence in addictions treatment settings: the role of current depressive symptoms on outcomes at 3 and 6 months. Nicotine Tob Res. 2015;17(8):937–45. 10.1093/ntr/ntv013 [DOI] [PubMed] [Google Scholar]
  • 17.Zawertailo L, Pavlov D, Ivanova A, Ng G, Baliunas D, Selby P. Concurrent e-cigarette use during tobacco dependence treatment in primary care settings: association with smoking cessation at three and six months. Nicotine Tob Res. 2016;19(2):183–9. 10.1093/ntr/ntw218 [DOI] [PubMed] [Google Scholar]
  • 18.Jarvis MJ, Wardle J. Social patterning of individual health behaviours: the case of cigarette smoking In: Marmot M, Wilkinson R, editors. Social determinants of health. 2nd ed Oxford: Oxford University Press; 2005. pp. 224–37. [Google Scholar]
  • 19.Hiscock R, Bauld L, Amos A, Platt S. Smoking and socioeconomic status in England: the rise of the never smoker and the disadvantaged smoker. J Public Health. 2012;34(3):390–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Corsi DJ, Boyle MH, Lear SA, Chow CK, Teo KK, Subramanian S. Trends in smoking in Canada from 1950 to 2011: progression of the tobacco epidemic according to socioeconomic status and geography. Cancer Causes Control. 2014;25(1):45–57. 10.1007/s10552-013-0307-9 [DOI] [PubMed] [Google Scholar]
  • 21.Hill S, Amos A, Clifford D, Platt S. Impact of tobacco control interventions on socioeconomic inequalities in smoking: review of the evidence. Tob Control. 2014;23(e2):e89–e97. 10.1136/tobaccocontrol-2013-051110 [DOI] [PubMed] [Google Scholar]
  • 22.Victora CG, Vaughan JP, Barros FC, Silva AC, Tomasi E. Explaining trends in inequities: evidence from Brazilian child health studies. Lancet. 2000;356(9235):1093–8. 10.1016/S0140-6736(00)02741-0 [DOI] [PubMed] [Google Scholar]
  • 23.Government of Ontario. Registered Persons Database (RPDB) [Internet]. Ottawa: Queen’s Printer for Ontario; 2017 [cited 2020 June 1]. https://data.ontario.ca/dataset/registered-persons-database-rpdb.
  • 24.Statistics Canada. 2006 Census of Population. Ottawa: Canada Post Corporation; 2006.
  • 25.Chiu M, Lebenbaum M, Lam K, Chong N, Azimaee M, Iron K, et al. Describing the linkages of the immigration, refugees and citizenship Canada permanent resident data and vital statistics death registry to Ontario’s administrative health database. BMC Med Inform Decis Mak. 2016;16(1):135 10.1186/s12911-016-0375-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kralj B. Measuring “rurality” for purposes of health-care planning: an empirical measure for Ontario. Ont Med Rev. 2000;67(9):33–52. [Google Scholar]
  • 27.Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol. 2006;59(1):67–76. 10.1016/j.jclinepi.2005.05.001 [DOI] [PubMed] [Google Scholar]
  • 28.Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study. Toronto: Institute for Clinical Evaluative Sciences; 2006.
  • 29.Hirdes J, Perez E, Curtin-Telegdi N, Prendergast P, Morris J, Ikegami N, et al. Ontario Mental Health Reporting System (OMHRS): minimum data set user’s manual. Ottawa: Canadian Institute for Health Information; 2005.
  • 30.Finkelstein MM. Do factors other than need determine utilization of physicians' services in Ontario? CMAJ. 2001;165(5):565–70. [PMC free article] [PubMed] [Google Scholar]
  • 31.Gibson D, Richards H, Chapman A. The national ambulatory care reporting system: factors that affect the quality of its emergency data. International Journal of Information Quality. 2008;2(2):97–114. [Google Scholar]
  • 32.Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person-level costing using administrative databases in Ontario. Working Paper Series. Vol 1. Toronto: Health System Performance Research Network; 2013 [cited on March 13, 2020]. https://hspn.ca/wp-content/uploads/2019/09/Guidelines_on_PersonLevel_Costing_May_2013.pdf
  • 33.Desveaux L, Agarwal P, Shaw J, Hensel JM, Mukerji G, Onabajo N, et al. A randomized wait-list control trial to evaluate the impact of a mobile application to improve self-management of individuals with type 2 diabetes: a study protocol. BMC Med Inform Decis Mak. 2016;16(1):144 10.1186/s12911-016-0381-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bernstein SL, Rosner J-M, Toll B. Cell phone ownership and service plans among low-income smokers: the hidden cost of quitlines. Nicotine Tob Res. 2016;18(8):1791–3. 10.1093/ntr/ntw042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Haight M, Quan-Haase A, Corbett BA. Revisiting the digital divide in Canada: the impact of demographic factors on access to the internet, level of online activity, and social networking site usage. Inf Commun Soc. 2014;17(4):503–19. [Google Scholar]
  • 36.McCrabb S, Twyman L, Palazzi K, Guillaumier A, Paul C, Bonevski B. A cross sectional survey of internet use among a highly socially disadvantaged population of tobacco smokers. Addict Sci Clin Pract. 2019;14(1):38 10.1186/s13722-019-0168-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fagerström K, Aubin H-J. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin. 2009;25(2):511–8. 10.1185/03007990802707568 [DOI] [PubMed] [Google Scholar]
  • 38.Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131(2):446–52. 10.1378/chest.06-1587 [DOI] [PubMed] [Google Scholar]
  • 39.Glazier R, Hutchison B, Kopp A. Comparison of family health teams to other Ontario primary care models, 2004/05 to 2011/12. Toronto: Institute for Clinical Evaluative Sciences; 2015.
  • 40.Manuel DG, Perez R, Bennett C, Laporte A, Wilton AS, Gandhi S, et al. A $4.9 billion decrease in health care expenditure: the ten-year impact of changing smoking, alcohol, diet and physical activity on health care use in Ontario. Toronto, ON: Institute for Clinical Evaluative Sciences; 2016.
  • 41.Statistics Canada. Figure 3, Proportion of the population living in rural areas, provinces and territories, 2006 and 2011 [Internet]. Ottawa: Statistics Canada; 2015 [cited 2019 November 29]. https://www12.statcan.gc.ca/census-recensement/2011/as-sa/98-310-x/2011003/fig/fig3_2-3-eng.cfm.
  • 42.Statistics Canada. Population and dwelling count highlight tables, 2016 census [Internet]. Ottawa: Statistics Canada; 2019 [cited 2020 January 24]. https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/hlt-fst/pd-pl/Table.cfm?Lang=Eng&T=703&SR=1&S=87&O=A&RPP=25.
  • 43.DesMeules M, Pong R, Read Guernsey J, Wang F, Luo W, Dressler M, et al. Rural health status and determinants in Canada. Health in Rural Canada. 2012:23–43. [Google Scholar]
  • 44.Manuel DG, Perez R, Bennett C, Rosella L, Choi BC. 900,000 days in hospital: the annual impact of smoking, alcohol, diet and physical activity on hospital use in Ontario. Toronto, ON: Institute for Clinical Evaluative Sciences; 2014.
  • 45.Mullen KA, Manuel DG, Hawken SJ, Pipe AL, Coyle D, Hobler LA, et al. Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes. Tob Control. 2017;26(3):293–9. 10.1136/tobaccocontrol-2015-052728 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mullen K-A, Coyle D, Manuel D, Nguyen HV, Pipe AL, Reid RD. Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada. Tob Control. 2015;24(5):489–96. 10.1136/tobaccocontrol-2013-051483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Rojewski AM, Baldassarri S, Cooperman NA, Gritz ER, Leone FT, Piper ME, et al. Exploring issues of comorbid conditions in people who smoke. Nicotine Tob Res. 2016;18(8):1684–96. 10.1093/ntr/ntw016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Chaiton M, Callard C. Mind the gap: disparities in cigarette smoking in Canada. Tob Use Insights. 2019;12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.David A, Esson K, Perucic A-M, Fitzpatrick C. Tobacco use: equity and social determinants In: Blas E, Kurup AS, editors. Equity, social determinants and public health programmes. Geneva: World Health Organization; 2010. pp. 199–218. [Google Scholar]
  • 50.Bauld L, Judge K, Platt S. Assessing the impact of smoking cessation services on reducing health inequalities in England: observational study. Tob Control. 2007;16(6):400–4. 10.1136/tc.2007.021626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Minian N, Noormohamed A, Baliunas D, Zawertailo L, Mulder C, Ravindran A, et al. Tailored versus generic knowledge brokering to integrate mood management into smoking cessation interventions in primary care settings: protocol for a cluster randomized controlled trial. JMIR Res Protoc. 2018;7(4):e111 10.2196/resprot.9715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Minian N, Baliunas D, Noormohamed A, Zawertailo L, Giesbrecht N, Hendershot CS, et al. The effect of a clinical decision support system on prompting an intervention for risky alcohol use in a primary care smoking cessation program: a cluster randomized trial. Implement Sci. 2019;14(1):85 10.1186/s13012-019-0935-x [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Stanton A Glantz

24 Apr 2020

PONE-D-20-07364

Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison

PLOS ONE

Dear Dr. Baliunas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 08 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Stanton A. Glantz

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1.    Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please ensure you have included the registration number for the clinical trial referenced in the manuscript.

3. Thank you for stating the following in the Competing Interests section:

"I have read the journal's policy and the authors of this manuscript have the following competing interests: DB reports grants from the Canadian Cancer Society Research Institute during the conduct of the study; she also reports grants from a Pfizer GRAND award, outside the submitted work. LZ reports grants from the Canadian Cancer Society Research Institute during the conduct of the study; she also reports grants from Pfizer GRAND Awards, outside the submitted work. PLS reports receiving grants from the Centre for Addiction and Mental Health, Ontario Ministry of Health and Long-Term Care, Health Canada, Canadian Institutes of Health Research, Canadian Cancer Society Research Institute, Canadian Partnership Against Cancer, Medical Psychiatry Alliance, Ontario Neurotrauma Foundation, the Patient-Centered Outcomes Research Institute, Bhasin Consulting Fund Inc and Pfizer Inc./Canada. PLS also reports serving on advisory boards and receiving consulting fees and honoraria from Pfizer Canada Inc., Johnson & Johnson Group of Companies, Evidera Inc., Miller Medical Communications, NVision Insight Group, Myelin & Associates, University of Ottawa Heart Institute, Royal College of Physicians and Surgeons of Canada, Royal Victoria Regional Health Centre, the University of Toronto Department of Family and Community Medicine, Northern Ontario School of Medicine, Canadian Partnership Against Cancer, Battle River Treaty 6 Healthcare, Lung Association of Nova Scotia, Exchange Summit, Toronto Public Health, Ontario Association of Public Health Dentistry and ECHO. PLS also reports that MedPlan Communications assisted in organizing Pfizer Canada Inc. Advisory Board events for which he was a consultant and that Pfizer Inc., Novartis, and Johnson & Johnson are vendors of record for providing free/discounted smoking cessation pharmacotherapy for research studies on which he is principal or co-investigator. No other author has competing interests to declare."

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a well-written paper about the STOP smoking cessation program in Ontario, Canada and its 11 specific sub-programs. The manuscript describes the variability in patient sociodemographic and clinical characteristics, and in healthcare service utilization.

Comments are in order of appearance.

Around line 15 in the introduction, please consider adding that it has been shown that NRT and counselling offered together are more effective than NRT alone.

When mentioning all the different data sources, starting in line 67, please include references to all of them, not just the ones you list in Appendix 2. If you do not want to include the information in the references, then just add them to Appendix 2. Some readers might want to follow up.

Footnotes to Table 2: “** suppressed due to small cell count (<6)” should not be a category between * and *** which are about the proportions of missing values. How about giving the small cell count an entirely different symbol?

Please spell out MHA the first time it appears in the text, it is only spelled out in one of the table legends.

The manuscript has a lot of detail about the different Ontario programs and about the characteristics of those enrolled in them. This information is valuable for future smoking cessation programs trying to reach different populations of smokers in this very specific region. What would add to the value of the paper would be somewhat more of a discussion of how this might (or might not) be generalizable outside of Ontario. Can you make any recommendations for readers who are not in Ontario or not even in Canada?

Figures: Figures should be more self-explanatory. Please consider the full names of the 11 sub-programs in the legend, including the years in which they were active.

Reviewer #2: This is an interesting and well-written manuscript describing sociodemographic, clinical and healthcare services utilization among smokers seeking smoking cessation services in Ontario Canada. The authors found that there were differences in the case-mix of populations that were reached by different cessation models, but less clear were the implication of these findings and how they could promote equity in access to cessation programs. I highlight some opportunities for clarifications below.

Abstract:

- The abstract would be clearer if the authors described in the background the different models of cessation care that are available to patients through the STOP program. While a long description is not necessary, a short description describing general approaches such as in-person, telephone etc. would be helpful.

- It is also not clear how the authors came up with the 107,302 case mix. For e.g., is this from a primary care populations and what clinics/hospitals were represented in this population. A brief description of the fact that the 107,302 people represent people who engaged in the STOP program would be helpful.

- The implications could be made clearer in terms of models that may be most effective for subpopulations with specific comorbidities, versus a more general population-based strategy to address tobacco use

Introduction

- The introduction is really clear in terms of its objective.

- My only suggestion is to provide a brief description of the 11 models or at least refer the reader to the Table and say that some were initiated by a referral (??) and some were self-referred. And who they were intended to target at the time of inception. i.e., were some models specifically more intensive because they were seeing a higher risk population (e.g., people in addition treatment). While some of this is described in the methods, I might bring some of this info up into the intro or at least refer the reader to the Table 1. I think some clarity on these models in the text would really help because when you get the results, it gets very confusing to keep all the models straight.

Methods

- Why was a long-term costs approach not considered in this study, i.e., costs past the index visit?

- Do the different STOP models for cessation, self-select for specific populations. For e.g., the web-based model may be best directed to a group that may not be very sick, whereas the addiction treatment model may target a higher needs group. If so, then costs would be vastly different based on the population seeking cessation treatment from a specific model. What information is cost adding in this analysis?

- How was missing data treated?

Results

- The most difficult part of the results is keeping the models straight and simplifying the results in the text so that it’s clear what the primary characteristics are for each of the models. One suggestion is to not present as many characteristics in the text but only emphasize the key ones so that the reader comes out with some key findings.

- Similarly Table 2 is really long and has a lot of information. Could you divide this into two tables?

- Also the sample sizes for some of the models are quite small, example CHC or nurse practitioner led clinics – is there utility in combining some of these smaller models? Or is the reasoning to keep them separate because they were intended to target specific populations.

Discussion

- The discussion is well-written. The main questions that I have that can be addressed in the discussion:

o whether these models catered to specific sub-populations at the outset and if that has changed over time.

o Are there cessation outcomes data available for patients enrolled in each of the STOP models. If there are, do the cessation rates reflect characteristics of the population seeking specific models?

o How much is reach defined by what is currently available and not what can be made available? i.e., if there were more access to web-based/telephone models in rural setting would there be equal reach compared to the NP based models. What can this study inform us about models that might be most impactful for low-income populations in Ontario.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Stanton A Glantz

16 Jun 2020

PONE-D-20-07364R1

Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison

PLOS ONE

Dear Dr. Baliunas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

You have done a nice job of responding to the reviewers' comments.

I only have one small request.  In the conclusion of the abstract you have vague statements that the healthcare system should ensure "some variation" in the cessation models used depending on patient and context.  The paper would be a lot better if you can make these statements more specific and concrete.  You have the relevant information in the Discussion.

Please submit your revised manuscript by Jul 31 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Stanton A. Glantz

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Jul 10;15(7):e0235709. doi: 10.1371/journal.pone.0235709.r004

Author response to Decision Letter 1


18 Jun 2020

We have revised the Discussion section of the Abstract to address the requested change, and made some further revision to the remainder of the Abstract in order to meet the word count limit.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Stanton A Glantz

22 Jun 2020

Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison

PONE-D-20-07364R2

Dear Dr. Baliunas,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

I have passed on your request to list Dr. Selby's email in the paper.  If you don't get an answer at this point, I suggest that you raise the question with the production staff as the manuscript moves forward into print.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Stanton A. Glantz

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Stanton A Glantz

29 Jun 2020

PONE-D-20-07364R2

Variability in patient sociodemographics, clinical characteristics, and healthcare service utilization among 107,302 treatment seeking smokers in Ontario: A cross-sectional comparison

Dear Dr. Baliunas:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Stanton A. Glantz

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Prevalent comorbidity algorithms and associated validation papers.

    (PDF)

    S2 Appendix. Population-based health administrative datasets used for cost ascertainment.

    (PDF)

    S3 Appendix. Mental health and addictions-related outcomes.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The dataset from this study, composed of STOP program data and ICES datasets, is held securely in coded form at ICES. While data sharing agreements and privacy legislation for the province of Ontario prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at https://www.ices.on.ca/DAS. Requests to access ICES data may be submitted to ICES Data & Analytic Services at das@ices.on.ca, with information available at https://www.ices.on.ca/DAS/Submitting-your-request.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES